Stomach cancer prevention breakthrough? 4,800-Person trial targets High-Risk bacteria

NCT ID NCT06943794

Not yet recruiting Prevention Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether finding and treating a high-risk type of H. pylori bacteria can prevent stomach cancer. Over 4,800 adults aged 40 and older will be assigned to either standard care or a program that screens for risky H. pylori subtypes and offers antibiotic treatment. Researchers will track cancer rates over 5 to 10 years to see if the strategy works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Helicobacter pylori eradication treatment (omeprazole or esomeprazole plus bismuth and two antibiotics)
What this could lead to: If successful, this could provide a targeted way to prevent stomach cancer by treating high-risk H. pylori infections before cancer develops.
What could go wrong: This is a large but early-stage prevention trial; results won't be known for years, and the approach may not reduce cancer rates as hoped. Antibiotic side effects or resistance could also limit effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC (STOMACH) CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric neoplasm gastric cancer prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC (STOMACH) CANCER

Contacts and locations

Locations

People's Hospital of Tongling City

Tongling, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.